Search results
Showing 31 to 45 of 1892 results for carers
NICE has published final draft guidance that does not recommend Enhertu (also called trastuzumab deruxtecan and made by Daiichi Sankyo) for treating advanced HER2-low breast cancer in adults.
Vitamin B12 deficiency in over 16s: diagnosis and management (NG239)
This guideline covers recognising, diagnosing and managing vitamin B12 deficiency in people aged 16 and over, including deficiency caused by autoimmune gastritis. It also covers monitoring for gastric cancer in people with autoimmune gastritis.
Find out more about being on a committee at NICE.
Achieving and demonstrating compliance with NICE TA and HST guidance
NICE guidance in the delivery of care means for patients, service users and carers Children, young people and adults will have access to...
Information to help people living with dementia, their family members and carers and their healthcare professionals discuss the options....
Putting our guidance into practice benefits patients and carers, healthcare professionals and organisations. Teams within NICE have a...
organisations for people who use health and social care services, their families and carers, and the public local Healthwatch...
This guideline covers preventing, identifying and managing latent and active tuberculosis (TB) in children, young people and adults. It aims to improve ways of finding people who have TB in the community and recommends that everyone under 65 with latent TB should be treated. It describes how TB services should be organised, including the role of the TB control board.
Digitally enabled therapies for adults with depression: early value assessment (HTE8)
Early value assessment (EVA) guidance on digitally enabled therapies for adults with depression....
Join Nice's Public Involvement Programme expert panel
the UK someone with experience in representing patients or carers, or who is a patient or carer (patient representative)....
NICE committee vacancies for patients, service users, carers and lay people
// Return to the our committees home page .
Evidence-based recommendations on belumosudil (Rezurock) for chronic graft-versus-host disease in people 12 years and over after 2 or more systemic treatments.
Evidence-based recommendations on nivolumab–relatlimab (Opdualag) for untreated advanced (unresectable or metastatic) melanoma in people 12 years and over.
Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer (TA951)
Evidence-based recommendations on olaparib (Lynparza) with abiraterone for untreated hormone-relapsed metastatic prostate cancer in adults.